BioSpace News Archive

Wolters Kluwer, Health today announced the launch of Ovid® Synthesis, a new suite of applications to power highly effective evidence-based workflows in the healthcare setting that complement Ovid’s premium medical content.

Development of advanced blockchain technologies and rapid integration of digital healthcare technologies and solutions in healthcare operations are other key factors expected to drive global blockchain in genomics market revenue growth over the forecast period.

According to Emergen Research, the global healthcare Internet of Things (IoT) market size was USD 1.15 Billion in 2020 and is expected to reach USD 5.52 Billion in 2028 and register a revenue CAGR of 21.6% during the forecast period, 2021-2028.

We’ve long been captivated by cloud, Internet of Things (IoT), artificial intelligence (AI), machine learning (ML), and blockchain technologies in the IT sector, but a lot has happened in the previous eighteen months as the world battled the pandemic.

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper, entitled “Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized, double-blind, sham-controlled PREMIUM II trial” in Cephalalgia, the official journal of the International Headache Society (IHS).

Inari Medical, Inc., a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, reported preliminary unaudited fourth quarter 2021 revenue.

Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today stated that its licensed partner, Allogene Therapeutics, Inc. (Nasdaq: ALLO) announced that the U.S. Food and Drug Administration (FDA) has lifted the hold on its clinical trials.

Labcorp, a leading global life sciences company, will release its financial results for the fourth quarter and full year 2021 before the market opens on Thursday, February 10, 2022.

The new study, led by the Institute for Molecular Medicine (IMM) and the National Institute of Aging in collaboration with the University of California, Irvine, and the University of California, San Diego, describes four vaccines designed to generate high levels of antibodies specific to various regions of pathological α-Synuclein.

ZIVO Bioscience, Inc., a biotech/agtech R&D company engaged in the development and commercialization of therapeutic, medicinal and nutritional product candidates derived from proprietary algal cultures, announces that Chairman of the Board John B. Payne has been named President and Chief Executive Officer of the Company.